Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
Charles M. Lieber is currently on paid leave from Harvard’s chemistry department after his arrest in January on charges of lying to the U.S. government about funds received from China.
A 41-year-old man from Richland, Wash. was convicted on 47 counts of fraud and drug related charges on Oct. 1, according to the U.S. Justice Department’s Eastern District of Washington.
New 50,000-square-foot facility will allow them to expand their services from development and Phase I/II to Phase III and manufacturing.
Results from multiple Phase III trials show consistent improvements in pain relief and physical function.
In the study published October 7th in Science Translational Medicine, Dr. Weiss et al shared that immunocytokines delivered systemically were effective in mice models and a pilot human trial.
10X Genomics just agreed to acquire ReadCoor, Inc., an innovator in the nascent field of in situ technology. The $350 million deal comes on the heels of 10x Genomics’ August acquisition of CartaNA AB, a Stockholm-based developer of in situ RNA analysis technology.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The investigational drug, ARO-AAT, is a potential first-in-class treatment that reduces the generation of mutant alpha-1 antitrypsin protein (Z-AAT), the primary contributor to liver disease progression in patients with AATLD.
Funds will also be utilized to enhance Corbus’ pipeline of novel endocannabinoid system-targeting drug candidates, and the company’s workforce will be reduced by up to 54%.